Skip to main content
Jianmin Pharmaceutical Group Co., Ltd. logo

Jianmin Pharmaceutical Group Co., Ltd. — Investor Relations & Filings

Ticker · 600976 ISIN · CNE000001HB7 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,559 across all filing types
Latest filing 2024-08-15 Interim / Quarterly Rep…
Country CN China
Listing Shanghai Stock Exchange 600976

About Jianmin Pharmaceutical Group Co., Ltd.

https://www.whjm.com/

Jianmin Pharmaceutical Group Co., Ltd. is a specialized pharmaceutical enterprise with a heritage dating back to 1637. The company focuses on the research, development, and manufacturing of Traditional Chinese Medicine (TCM) and modern healthcare products. Its core portfolio emphasizes pediatric health, gynecological treatments, and chronic disease management. Key products include Longmu Zhuanggu Granules, recognized for supporting bone development and overall health in children. The group integrates traditional pharmacological wisdom with contemporary biotechnology and standardized production processes. Jianmin Group operates through a comprehensive value chain encompassing raw material sourcing, advanced manufacturing, and a distribution network. By leveraging its status as a time-honored brand, the company maintains a strong market position in the pediatric TCM segment while expanding its presence in general wellness and prescription drug markets.

Recent filings

Filing Released Lang Actions
健民集团2024年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2024 半年度报告摘要' which translates to '2024 Half-Year Report Summary'. It contains detailed financial data for the half-year period, including total assets, net profit, revenue, cash flow, and shareholder information. The document explicitly states it is an unaudited half-year report summary and references the full half-year report for more details. The content includes substantive financial data and analysis for a period shorter than a full fiscal year, consistent with an Interim / Quarterly Report. The document length is 2874 characters, which is relatively short but contains actual financial data, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2024
2024-08-15 Chinese
健民集团2024年半年度报告全文
Interim / Quarterly Report Classification · 100% confidence The document is titled "2024 年半年度报告" which translates to "2024 Semi-Annual Report" or "Interim Report". It contains detailed financial data, management discussion and analysis, company information, accounting data, and business overview for the first half of 2024. The length is substantial (15,000 characters), and it includes actual financial statements and substantive financial analysis. The content matches the definition of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year. It is not merely an announcement or a certification, but a full report. Therefore, the correct classification is IR with high confidence. H1 2024
2024-08-15 Chinese
健民集团监事会关于2024年半年度报告的审核意见
Audit Report / Information Classification · 95% confidence The document is a supervisory board's audit opinion on the company's 2024 semi-annual report. It references the 2024 half-year report and confirms compliance with regulations and procedures. The document is very short (346 characters) and does not contain actual financial data or the report itself, but rather an opinion on the report. This fits the criteria of an Audit Report / Information (AR) as it is a standalone audit opinion related to a specific financial report period, not the full report itself or a mere announcement. H1 2024
2024-08-15 Chinese
健民集团第十届董事会第二十五次会议决议公告
Board/Management Information Classification · 95% confidence The document is a board meeting resolution announcement from 健民药业集团股份有限公司 (Jianmin Pharmaceutical Group Co., Ltd.) regarding decisions made at the 25th meeting of the 10th Board of Directors. It includes approval of the 2024 half-year report, investment projects, and establishment of a subsidiary. The document is a formal announcement of board decisions rather than the actual half-year financial report itself. It references the half-year report being disclosed on official websites and newspapers, indicating this document is a board/management information announcement about the board's resolutions. Therefore, it fits best under Board/Management Information (MANG). The document length is short (999 characters), and it is not the full interim report but a meeting resolution notice.
2024-08-15 Chinese
健民集团关于召开2024年半年度业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the scheduling and details of a 2024 half-year performance explanation meeting (业绩说明会) for investors. It specifies the date, time, location, and participation method for the meeting, which will discuss the company's 2024 half-year operating results and financial indicators. The document does not contain actual financial statements or detailed financial analysis but rather invites investors to attend the meeting where such information will be discussed. The document length is 1543 characters, which is relatively short and consistent with an announcement rather than a full report. According to the classification rules, this type of document is an Investor Presentation (IP) or a notice about an investor meeting, but since it is announcing the meeting itself and not the presentation materials, it fits best under Investor Presentation (IP) as it focuses on financials, strategy, and market position through the meeting. It is not an Interim Report (IR) because it lacks substantive financial data, nor is it a Report Publication Announcement (RPA) because it does not announce the release of a report but the meeting to discuss it. Therefore, the best classification is Investor Presentation (IP).
2024-08-08 Chinese
健民集团关于获得《药品注册证书》的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the receipt of drug registration certificates from the National Medical Products Administration. It details the approval of two pharmaceutical products, their registration information, market status, and potential impact on the company. The document is an official announcement of a regulatory approval event, not a financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial data. The document length is 2242 characters, which is relatively short and focused on a specific regulatory event. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-07-05 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.